NEW YORK (TheStreet) -- Shares of GlaxoSmithKline (GSK) - Get Report were edging lower in early morning trade on Wednesday after the company named Brian McNamara as CEO of its consumer healthcare unit, replacing Emma Walmsley effective immediately.
McNamara was previously head of Europe and Americas in the healthcare company's consumer healthcare division.
Walmsley will assume the role of CEO at GlaxoSmithKline after Andrew Witty retires in March.
Separately, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
TheStreet Ratings rated this stock as a "hold" with a ratings score of C.
The company's strengths can be seen in multiple areas, such as its good cash flow from operations, expanding profit margins and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity.
You can view the full analysis from the report here: GSK